康哲药业：重磅品种芦可替尼获批上市，未来增长可期-20260202

Investment Rating - The report assigns a positive outlook on China Medical System Holdings, indicating a potential for significant revenue growth from the newly approved ruxolitinib cream [1][3]. Core Insights - The approval of ruxolitinib cream for treating non-segmental vitiligo is expected to drive substantial sales growth, with management projecting revenues of at least CNY 500 million in 2026 and doubling in 2027, reaching a peak of no less than CNY 6 billion within 4-5 years [3][11]. - The cream is positioned to fill a market gap due to the limitations of existing therapies for vitiligo, with a strong demand from patients willing to pay for better efficacy and fewer side effects [4][12]. - The company has initiated pilot applications of the cream in Hainan, with over 7,700 patients already using it before formal approval, indicating strong early adoption [2][10]. Summary by Sections Product Approval and Market Strategy - On January 30, the company’s subsidiary Dermavon received approval from the NMPA for ruxolitinib cream, which is an innovative formulation for treating non-segmental vitiligo in patients aged 12 and above [1][8]. - The company has established exclusive rights for the development and commercialization of the product in several regions, including Mainland China and Southeast Asia [1][8]. Market Potential and Revenue Projections - Management anticipates that the cream will generate revenues of at least CNY 500 million in 2026, with expectations to double in 2027 and reach a peak revenue of no less than CNY 6 billion [3][11]. - The pricing strategy indicates that the listed price will be lower than the previous pilot price of CNY 6,800 per tube [3][11]. Competitive Landscape - Existing treatments for vitiligo have clinical limitations, and ruxolitinib cream is expected to provide a more effective solution, particularly for patients with facial involvement [4][12]. - The cream's efficacy has been supported by real-world data from the Hainan pilot zone, aligning with international clinical study results [4][12]. Future Developments - The company is also focusing on the potential use of ruxolitinib cream for mild-to-moderate atopic dermatitis, with plans to submit a marketing application soon [4][13].